Taking fish oil supplements with at least 2.7 grams of EPA and DHA daily for three months or more may help reduce morning stiffness and joint pain in people with rheumatoid arthritis, and sometimes reduce the need for painkillers, but it doesn't consistently lower measurable inflammation in the blood.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A high-quality systematic review and meta-analysis of long-term, double-blind RCTs would determine whether omega-3 supplementation at 2.7 g/day EPA/DHA consistently reduces disease activity (DAS28) and NSAID use in RA, while controlling for baseline vitamin D, smoking, and BMI.
A systematic review and meta-analysis of at least 15 double-blind, placebo-controlled RCTs involving 1,000+ adults with established RA, all using standardized 2.7–3.0 g/day EPA/DHA supplementation for 6–12 months, with primary outcomes of DAS28, HAQ, and NSAID consumption, and secondary outcomes of CRP, IL-6, and joint erosion on imaging, stratified by baseline omega-3 status and smoking history.
A large, long-term RCT would determine whether omega-3 supplementation directly causes reduction in RA disease activity and NSAID dependence, independent of placebo effects or lifestyle changes.
A multicenter, double-blind, placebo-controlled RCT with 500 participants aged 40–75 with moderate RA, randomized to 3.0 g/day EPA/DHA or olive oil placebo for 12 months, with primary outcome DAS28 change, secondary outcomes including HAQ, CRP, ESR, joint ultrasound scores, and NSAID use, with strict dietary monitoring and control for smoking, vitamin D, and physical activity.
A prospective cohort study would determine whether habitual fish or omega-3 intake predicts slower progression of RA disease activity over 5–10 years, adjusting for confounders.
A prospective cohort of 2,000 adults with early RA or high-risk serology (ACPA+) followed for 10 years, with annual dietary assessments via food frequency questionnaires and biomarkers (plasma EPA/DHA), measuring DAS28, joint damage on X-ray, and NSAID use annually, adjusting for smoking, BMI, medication, and physical activity.
A case-control study would determine whether individuals with high RA disease activity have significantly lower historical omega-3 intake compared to those with low activity, matched for confounders.
A case-control study comparing 300 RA patients with high disease activity (DAS28 >5.1) to 300 matched controls with low activity (DAS28 <3.2), using validated food recall over the prior 5 years to assess omega-3 intake, matched for age, sex, smoking, BMI, and DMARD use.
A cross-sectional study would determine whether current omega-3 intake correlates with current RA disease activity at a single time point.
A cross-sectional survey of 1,000 RA patients measuring current dietary omega-3 intake via 3-day food diary and plasma EPA/DHA levels, alongside DAS28 and CRP at the same visit, adjusting for age, sex, medication, and BMI.